Metagenomi Therapeutics (MGX) EBT (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly EBT of -$23.0 million for Q1 2026, up 7.59% year-over-year from -$21.4 million in Q1 2025, and down 2.47% quarter-over-quarter from -$22.5 million in Q4 2025.
Metagenomi Therapeutics (MGX) EBT (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported EBT for 4 consecutive years, with -$23.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 7.59% year-over-year to -$23.0 million; the TTM figure through Mar 2026 stood at -$86.0 million (down 3.2% YoY), while the FY2025 annual figure was -$87.9 million, down 5.21% from the prior year.
- EBT eased to -$23.0 million in Q1 2026 per MGX's latest filing, from -$22.5 million in the prior quarter.
- Across five years, EBT topped out at -$11.1 million in Q2 2023 and bottomed at -$25.1 million in Q1 2024.
- Historically, EBT has averaged -$19.6 million across 4 years, with a median of -$20.6 million in 2025.
- Annual changes were most pronounced in 2024 — EBT plunged 80.45% — and 2025, when it climbed 8.58%.
- Metagenomi Therapeutics' EBT stood at -$16.6 million in 2023, then tumbled by 48.52% to -$24.6 million in 2024, then increased by 8.58% to -$22.5 million in 2025, then slipped by 2.47% to -$23.0 million in 2026.
- Business Quant data shows MGX's EBT at -$23.0 million in Q1 2026, -$22.5 million in Q4 2025, and -$20.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | -27.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.48 Mn |
| Mar 31, 2026 | -23.05 Mn |
| Dec 31, 2025 | -22.49 Mn |
| Sep 30, 2025 | -20.63 Mn |
| Jun 30, 2025 | -19.86 Mn |
| Mar 31, 2025 | -24.94 Mn |
| Dec 31, 2024 | -24.61 Mn |
| Sep 30, 2024 | -20.88 Mn |
| Jun 30, 2024 | -12.94 Mn |
| Mar 31, 2024 | -25.15 Mn |
| Dec 31, 2023 | -16.57 Mn |
| Sep 30, 2023 | -18.61 Mn |
| Jun 30, 2023 | -11.11 Mn |
| Mar 31, 2023 | -13.94 Mn |